Adenovirus E3-19K Mutation Enhances Oncolytic Spread
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and radiotherapy, are limited in their ability to effectively target and cure advanced cancer due to toxicity issues and the inability to selectively target tumor cells, necessitating the development of more selective and potent biotechnological strategies like gene therapy and virotherapy.
Innovation Solution
The modification of adenoviruses with a mutation in the endoplasmic reticulum retention domain of the E3-19K protein to enhance their release from infected cells, increasing their oncolytic potency and selectivity towards tumor cells, thereby improving cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adenoviruses are used for cancer virotherapy, then selective replication in tumor cells is achieved, but the release and spread of virus from infected cells is limited
Solution Approach 1:
The invention applies parameter changes by mutating the endoplasmic reticulum retention domain of the E3-19K protein in the adenovirus genome. This genetic modification changes the cellular localization of the E3-19K protein from endoplasmic reticulum retention to plasma membrane localization, which subsequently enhances virus release and spread from infected tumor cells, thereby improving oncolytic potency
Solution Approach 2:
The invention extracts or removes the endoplasmic reticulum retention domain (specifically the KK motif at the carboxy-terminus) of the E3-19K protein. This extraction eliminates the retention signal that keeps the protein trapped in the endoplasmic reticulum, allowing the protein to be transported to the plasma membrane where it enhances virus release, thus resolving the limitation on virus spread
2Reliability
If conventional cancer treatments (chemotherapy and radiotherapy) are used, then broad cancer targeting is achieved, but selectivity towards tumor cells and potency are limited due to toxicity to normal cells
Solution Approach 1:
The invention applies self-service by engineering the adenovirus to selectively replicate only in tumor cells through the mutant E3-19K protein's enhanced release function. The virus autonomously targets and destroys tumor cells through oncolysis without requiring external intervention or affecting normal cells, as the mutant protein's plasma membrane localization enables selective virus spread from tumor cell to tumor cell
Solution Approach 2:
The invention applies local quality by creating a localized effect where the mutant E3-19K protein is specifically expressed and localized in tumor cells infected by the engineered adenovirus. The plasma membrane localization of E3-19K in tumor cells creates a localized enhancement of virus release and spread, confining the therapeutic effect to tumor tissue while sparing normal cells
Data Source
AI summary
The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.